Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Document › Details

Eckert & Ziegler SE. (12/13/24). "Press Release: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW". Berlin.

Region Region Japan
Organisations Organisation Eckert & Ziegler Radiopharma GmbH
  Group Eckert & Ziegler (Group)
  Organisation 2 Novartis Pharma K.K. (NPKK)
  Group Novartis (Group)
Products Product GalliaPharm® 68Ge/68Ga Radionuclide Generator
  Product 2 radionucleotide therapy
Persons Person Schöpflin, Jan (Eckert & Ziegler 202412 Marketing)
  Person 2 Riehle, Karolin (Eckert & Ziegler 202212 Investor Relations + PR)
     


Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge diagnostic tools including 68Ga-PSMA-11 in Japan. For GalliaPharm®, Novartis Pharma K.K., will manage safety information and distribution of the product in Japan.

GalliaPharm® is widely used as a high-quality GMP grade generator for Gallium-68, supporting the production of radiopharmaceuticals for positron emission tomography (PET) imaging, particularly in oncology including the diagnosis of prostate cancer through PSMA imaging. An approval in Japan will provide the local healthcare community with an accessible and reliable tool to label Gallium-68 radiopharmaceuticals, offering new precision in diagnostic imaging that may improve early disease detection and patient outcomes.

“This step with the MHLW for us is a critical one,” stated Dr. Deljana Werner, Head of QA and Regulatory Affairs for the Medical Division of Eckert & Ziegler SE. “As a company committed to advancing nuclear medicine globally, we see GalliaPharm®’s entry into the Japanese market as a pivotal opportunity to support medical professionals in enhancing patient care through precise and innovative imaging solutions.”

By seeking approval in Japan, Eckert & Ziegler reinforces its commitment to meeting the specific needs of diverse healthcare markets, tailoring its innovations to support local advancements in nuclear medicine. This step not only underscores the company’s dedication to providing advanced radioisotopes for medical applications worldwide, but also strengthens its position as a trusted partner in the evolving landscape of radiopharmaceuticals.


About Eckert & Ziegler SE

Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.


Contact

Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
[email protected] / [email protected]
Tel.: +49 (0) 30 / 94 10 84-138; https://ezag.com

   
Record changed: 2025-01-21

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Eckert & Ziegler (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top